Novartis Patents and Rigel. Patents licensed hereunder shall be prosecuted and maintained by Novartis and Rigel, respectively, at such Party's option and its own expense; provided, however, that the Parties shall consult with and consider the comments of the CMC with respect to the prosecution of applications for such patents.
Appears in 4 contracts
Samples: Collaboration Agreement (Rigel Pharmaceuticals Inc), Collaboration Agreement (Rigel Pharmaceuticals Inc), Collaboration Agreement (Rigel Pharmaceuticals Inc)
